Briefing on the Fundamentals of Ambrx Biopharma (AMAM)

By Scott Lee • Friday, April 21 09:50 • Permanent Link

Ambrx Biopharma moved -2.5% this morning session, trading between a high of $12.0 and a low of $11.3803 per share. Yesterday the stock finished at $11.7 per share.

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The small-cap biotechnology: biological products (no diagnostic substances) company is based in the United States, and over the last twelve months it has returned a dividend yield of None%. Ambrx Biopharma has trailing twelve months earnings per share (EPS) of -2.29, which at today's prices amounts to a price to earnings (P/E) ratio of -5.0.

Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of -1.93. Usually a PEG ratio between zero and one indicates a potentially undervalued company.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.